Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

348.35
+25.337.84%
Post-market: 348.350.00000.00%19:49 EDT
Volume:382.11K
Turnover:130.08M
Market Cap:7.69B
PE:-15.91
High:348.35
Open:328.50
Low:326.70
Close:323.02
Loading ...

Madrigal: Q4 Earnings Snapshot

Associated Press Finance
·
26 Feb

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Revenue $103.3M, vs. FactSet Est of $99.1M

MT Newswires Live
·
26 Feb

Madrigal Pharmaceuticals Q4 2024 GAAP EPS $(2.71) Beats $(4.16) Estimate, Sales $103.22M Beat $98.56M Estimate. Cash And Equivalents Of $931.3M

Benzinga
·
26 Feb

BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.71

Reuters
·
26 Feb

Madrigal Pharmaceuticals Q4 Operating Expenses USD 170.317 Million

THOMSON REUTERS
·
26 Feb

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire
·
26 Feb

Madrigal Announces New Two-Year Data From the Compensated Mash Cirrhosis Arm of the Maestro-Nafld-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (Resmetirom) in Patients With Compensated Mash Cirrhosis

THOMSON REUTERS
·
26 Feb

Madrigal Pharmaceuticals Inc - Safety Profile of Rezdiffra Consistent With Other Trials

THOMSON REUTERS
·
26 Feb

Madrigal Pharmaceuticals Inc - Reports Positive Two-Year Results From Phase 3 Trial

THOMSON REUTERS
·
26 Feb

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire
·
26 Feb

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
25 Feb

John Paulson's Strategic Moves: Thryv Holdings Inc. Takes Center Stage with a 2.04% Portfolio Impact

GuruFocus.com
·
15 Feb

U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku

Reuters
·
14 Feb

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISI

TIPRANKS
·
13 Feb

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

GlobeNewswire
·
12 Feb

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Zacks
·
29 Jan